NASD · Healthcare · Biotechnology · USA
Seer Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Seer Inc offers the Proteograph Product Suite, a proteomics platform enabling researchers to conduct comprehensive, unbiased protein analysis at scale. The offering combines consumable assays, automation equipment, and analytical software to support protein discovery, disease investigation, and biomarker development. The company serves customers in research, drug development, sample repositories, and clinical study settings worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Seer Inc stock.
Undervalued: intrinsic value $2.95 per share, market price $1.46, margin of safety 50.5% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $2.95; the price of $1.46 is 51% below that value.
8 more funds hold it; the full list is part of the paid plan.
6 more in this industry show a wider margin of safety.
SEER is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.95; the price of $1.46 is 51% below that value.
$2.95 per share (as of the 2026-11-17 close), against a market price of $1.46. That is a margin of safety of 50.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.